Whole body MRI and PET/CT in haematological malignancies

Cancer Imaging

Volumn 7, Issue SPEC. ISS. A, 2007, Pages

  Lin, Chieh ^a   Luciani, Alain ^a   Itti, Emmanuel ^a   Haioun, Corinne ^a   Rahmouni, Alain ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Functional imaging; MRI; PET CT; Treatment response; Whole body

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON 11; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; METHIONINE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ACCURACY; BONE MARROW METASTASIS; BONE MARROW SCINTISCANNING; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; FALSE NEGATIVE RESULT; FUNCTIONAL ANATOMY; HEALTH CARE QUALITY; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LYMPH NODE BIOPSY; LYMPHOMA; MEDIASTINUM METASTASIS; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; MYELOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PATIENT CARE; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; TUMOR VASCULARIZATION; WHOLE BODY CT; WHOLE BODY IMAGING; WHOLE BODY MRI; WHOLE BODY PET; BLOOD DISEASE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOGRAPHY; RISK ASSESSMENT; SCINTISCANNING;

CONTRAST MEDIA; HEMATOLOGIC NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; PROGNOSIS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 35848955191     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2007.9004     Document Type: Review

References (29)

1. Schmidt GP, Haug AR, Schoenberg SO, Reiser MF. Whole-body MRI and PET-CT in the management of cancer patients. Eur Radiol 2006; 16: 1216-25.
2. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 2004; 22: 275-82.
3. Schmidt GP, Baur-Melnyk A, Herzog P, et al. High-resolution whole-body MRI tumor staging with the use of parallel imaging versus dual-modality PET-CT: experience on a 32-channel system. Invest Radiol 2005; 40: 743-53.
4. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86.
5. Tatsumi M, Cohade C, Nakamoto, Y, Fishman EK, Wahl RL. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 2005; 237:1038-45.
6. Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 2007; 48: s19-27.
7. 18F]Fluoro-2-deoxy-D-glucose positron eniission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376-81.
8. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-9.
9. Dupuis J, Gaulard P, Hemery F, et al. Respective prognostic values of germinal center phenotype and early (18)fluorodeoxy-glucose-positron emission scanning tomography in previously untreated patients with diffuse large B-cell lymphoma. Haematologica 2007; 92: 778-83.
10. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514-23.
11. Lin C, Itti R, Haioun C, et al. Early FDG-PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007 (in press).
12. Mulligan ME, Badros AZ. PET/CT and MR imaging in myeloma. Skeletal Radiol 2007; 36: 5-16.
13. Durie BG, Waxman AD, D'Agnolo A, Williams CM. Whole-body F18-FDG PET identifies high-risk myeloma. J Nucl Med 2002; 43: 1457-63.
14. Durie BG; Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the scientific advisors of the international myeloma foundation. Hematol J 2003; 4: 379-98.
15. Breyer III RJ, Mulligan ME, Smith SE, Line BR, Badros AZ. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol 2006; 35: 632-40.
16. 11C-methionine PET/CT: initial experience. Radiology 2007; 242: 498-508.
17. Kellenberger CJ, Miller SF, Khan M, Weitzman S, Babyn PS. Initial experience with FSE STIR whote-body MR imaging for staging lymphoma in children. Eur Radiol 2004; 14: 1829-41.
18. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003; 290: 3199-206.
19. Ballon D, Watts R, Dyke JP, et al. Imaging therapeutic response in human bone marrow using rapid whole-body MRI. Magn Reson Med 2004; 52: 1234-8.
20. Schmidt GP, Schoenberg SO, Reiser MF, Baur-Melnyk A. Whole body MR imaging of bone marrow. Eur J Radiol 2005; 55: 33-40.
21. Ghanem N, Lohrmann C, Engelhardt M, et al. Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol 2006; 16: 1005-14.
22. Baur-Melnyk A, Buhmann S, Durr HR, Reiser M. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 2005; 55: 56-63.
23. Walker RW, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myetoma: diagnostic and clinical implications. J Clin Oncol 2007; 25: 1121-8.
24. Rahmouni A, Divine M, Mathieu D, et al. MR appearance of multiple myeloma of the spine before and after treatment. AJR Am J Roentgenol 1993; 160: 1053-7.
25. Moulopoulos LA, Dimopoulos MA, Alexanian R, Leeds NE, Libshitz HI. Multiple myeloma: MR pattern of response to treatment. Radiology 1994; 193: 441-6.
26. Sezer O, Niemoller K, Eucker J, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 2000; 79: 574-7.
27. Baur A, Barti R, Pellengahr C, Baltin V, Reiser M. Neovascularization of bone marrow in patients with diffuse multiple myeloma. Cancer 2004; 101: 2599-604.
28. Rahmouni A, Montazel JL, Divine M, et al. Bone marrow with diffuse tumor infiltration in patients with lymphoproliferative diseases: dynamic gadolinium-enhanced MR imaging. Radiology 2003; 229: 710-7.
29. Hillengass J, Wasser K, Delorme S, et al. Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced MRI is a predictor of event-free survival in progressive multiple myeloma. Clin Cancer Res 2007; 13: 475-81.